Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPER-Trial: Empagliflozin vs Glimepiride for Progression of Diabetic Retinopathy
2016-000825-38Phase 4Terminated
- Sponsor
- Hannover Medical School
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in diabetic retinopathy (DR) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hannover Medical School. Primary endpoint: Microaneurysm formation rate over 12 months. Started Jul 2016; status: terminated.
02
Drugs
empagliflozin
03
Conditions
diabetic retinopathy (DR)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000825-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000825-38.